Company: PCRX
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001104659-25-041219
Chunk: 58

Company: Pacira BioSciences, Inc.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 58
---
 Kristen Williams(4)         | ​ | ​ | ​                  | ​ |       ― | ​ | ​ | ​ | ​                                      | ​ |         ― | ​ | ​ | ​ | ​          | ​ | 88,000 | ​ | ​ | ​ | ​                              | ​ | 2,606,742 | ​ | ​ |
| Daryl Gaugler(4)            | ​ | ​ | ​                  | ​ |       ― | ​ | ​ | ​ | ​                                      | ​ |         ― | ​ | ​ | ​ | ​          | ​ | 88,000 | ​ | ​ | ​ | ​                              | ​ | 2,606,742 | ​ | ​ |
| Jonathan Slonin             | ​ | ​ | ​                  | ​ |  10,000 | ​ | ​ | ​ | ​                                      | ​ |   131,038 | ​ | ​ | ​ | ​          | ​ | 59,300 | ​ | ​ | ​ | ​                              | ​ | 1,717,324 | ​ | ​ |

(1) The stock option grants have an exercise price equal to the closing price of our stock price on the grant date, and vest as to 25% of the options shares on the first anniversary of the grant date, with the remaining option shares vesting in equal quarterly installments over the subsequent three years, provided that the named executive officer remains in continuous service with us as of each vesting date. The RSU awards vest in four equal annual installments beginning on the first anniversary of the vesting date, provided that the named executive officer remains in continuous service with us as of each vesting date.

70 | investor.pacira.com

TABLE OF CONTENTS Executive Compensation During 2024, Messrs. Lee and Cross received stock options in connection with their commencement of employment, and Dr. Slonin received stock options in connection with his promotion to Chief Medical Officer. For more information on Dr. Slonin’s promotional grants, see "Jonathan Slonin Promotion to Chief Medical Officer" below. (2) Amounts reflect the aggregate grant date fair value of grants made in each respective fiscal year computed in accordance with stock-based compensation accounting rules (FASB ASC Topic 718, Stock Compensation). Assumptions used in the calculations of these amounts are included in Note 13 to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2024.